NCT05970731 - Directed Topical Drug Delivery for Treatment for PASC Hyposmia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions

Post Acute Sequelae Covid-19 Hyposmia

Interventions

DRUG

Beclomethasone

84 mcg of Beclomethasone administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.

OTHER

Placebo

Placebo (0.9% sodium chloride) administered topically on an intranasal microsponge, placed in the olfactory cleft using a nasal endoscope, on day 1 and repeated on day 14.

DEVICE

Microsponge

Drug delivery using chitosan-based biocompatible microsponge

Trial Locations (1)

27710

Duke University Medical Center, Durham